证券之星消息，1月6日互联网医疗板块较上一交易日上涨1.5%，塞力医疗领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。互联网医疗板块个股涨跌见下表： 从资金流向上来看，当日互联网医疗板块主力资金净流出17.51亿元，游资资金净流出3.81亿元，散户资 金净流入21.33亿元。互联网医疗板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - JD Health (06618) is expected to outperform market expectations in the second half of 2025, driven by a surge in flu cases leading to increased demand for pharmaceuticals [1] Group 1: Financial Performance - JD Health's stock rose over 6%, reaching HKD 62 with a trading volume of HKD 411 million [1] - Nomura forecasts that JD Health's revenue for Q4 2025 will reach RMB 20 billion, representing a year-on-year growth of 22% [1] - The growth in Q4 2025 is attributed to sales increases in pharmaceuticals (30%), nutritional products (20%), and medical devices (10%) [1] Group 2: Market Trends - The increase in flu cases in Q4 2025 is expected to significantly boost pharmaceutical sales, contributing a high single-digit percentage to total sales [1] - The sales of medical devices, such as home oxygen concentrators, are also anticipated to rise due to the flu season [1] - Nutritional brands will continue effective marketing campaigns in Q4 2025, reinforcing their growth trajectory [1] Group 3: Strategic Partnerships - CICC noted strong revenue performance for JD Health in 2025, with quarterly growth rates around 25% year-on-year for Q1 to Q3 [1] - The company has signed strategic cooperation agreements with pharmaceutical companies like Eli Lilly, Innovent Biologics, and Bayer China, enhancing its unique business model of launching new drugs online [1] - The ongoing trend of increasing original drug volumes is expected to support strong revenue performance in Q4 2025 [1]

Core Viewpoint - JD Health is expected to outperform market expectations in the second half of 2025, primarily due to a surge in flu cases driving up demand for pharmaceuticals [1] Group 1: Financial Performance - JD Health's revenue for Q4 2025 is projected to reach 20 billion RMB, representing a year-on-year growth of 22%, driven by sales growth in pharmaceuticals, nutritional products, and medical devices at 30%, 20%, and 10% respectively [1] - The company has shown strong revenue performance throughout 2025, with each quarter from Q1 to Q3 achieving approximately 25% year-on-year growth [1] - The overall revenue growth for JD Health in 2025 is anticipated to be close to 25% year-on-year [1] Group 2: Market Dynamics - The increase in flu cases in Q4 2025 is expected to significantly contribute to pharmaceutical sales, accounting for a high single-digit percentage of total pharmaceutical revenue [1] - The sales of medical devices, such as home oxygen concentrators, are also expected to rise due to the flu outbreak [1] - JD Health's nutritional brands will continue to implement effective marketing strategies in Q4 2025, reinforcing their growth trajectory [1] Group 3: Strategic Partnerships - JD Health has signed strategic cooperation agreements with pharmaceutical companies such as Eli Lilly, Innovent Biologics, and Bayer China, enhancing its business model of launching new drugs online [1]

消息面上，野村发表报告，预计京东健康2025年下半年业绩将好过市场预期，主要因2025年第四季流感 病例激增带动药品需求上升。该机构预估京东健康2025年第四季营收将达200亿元人民币，按年增长 22%，受惠来自药品/营养品/医疗器材业务分别实现30%、20%及10%按年销售增长。2025年第四季流感 病例扩散带动相关药品，占药品销售额高单位数百分比，及医疗设备如家用氧气浓缩机销售。与此同 时，营养品牌在2025年第四季持续推行有效营销活动，强化其稳健增长态势。 中金发布研报称，考虑到原研品类放量趋势依旧且流感品种需求强劲，上调京东健康25年及26年收入预 测2%至725亿元及817亿元，同时考虑毛利率改善趋势及潜在利息收入波动的综合影响，该行分别上调 25年及26年non-IFRS净利润4%及1%至65亿元及64亿元。首次引入27年收入预测912亿元及non-IFRS净 利润预测68亿元。考虑到近期板块表现略有波动，基于SOTP维持目标价71.4港币不变(23%上行空间)， 维持跑赢行业评级。 金吾财讯 | 京东健康(06618)股价上行，截至发稿，涨5.58%，报61.45港元，成交额2.3亿港元。 消息 ...

Core Viewpoint - Nomura forecasts that JD Health's performance in the second half of 2025 will exceed market expectations, primarily driven by a surge in flu cases in the fourth quarter, leading to increased demand for pharmaceuticals [1] Revenue Projections - Nomura estimates that JD Health's revenue in the fourth quarter of 2025 will reach 20 billion yuan, representing a year-on-year growth of 22% [1] - The growth is attributed to the pharmaceutical, nutritional, and medical device segments, which are expected to achieve year-on-year sales growth of 30%, 20%, and 10% respectively [1] Market Drivers - The spread of flu cases in the fourth quarter is expected to significantly contribute to pharmaceutical sales, accounting for a high single-digit percentage of total pharmaceutical revenue [1] - Sales of medical devices, such as home oxygen concentrators, are also anticipated to increase due to the flu outbreak [1] Marketing Strategies - Nutritional brands are expected to continue effective marketing campaigns in the fourth quarter, reinforcing their robust growth trajectory [1]

Core Viewpoint - CICC has raised JD Health's revenue forecasts for 2025 and 2026 by 2% to 72.5 billion yuan and 81.7 billion yuan respectively, driven by the ongoing growth of original drug categories and strong demand for flu products [1] Group 1: Revenue Performance - The company is expected to show strong revenue growth, with a projected year-on-year increase of nearly 25% for the entire year of 2025, supported by the continuous release of original drugs and the rising demand for flu prevention since Q4 2025 [2] - In the first three quarters of 2025, the company achieved a quarterly revenue growth rate of approximately 25% year-on-year [2] Group 2: Profitability Outlook - The company's non-IFRS net profit margins for the first three quarters of 2025 were 10.6%, 9.7%, and 11.1%, showing varying degrees of improvement year-on-year, primarily due to increased advertising and marketing investments by pharmaceutical and health product companies [3] - Despite the typical increase in expenditures during Q4 2025, the company is expected to maintain a stable profit margin for the year, reflecting strong competitive capabilities [3] - The company has significant cash reserves, and potential fluctuations in interest income due to interest rate cuts may impact non-IFRS net profit in the coming quarters [3]

Group 1 - The core viewpoint is that JD Health's revenue forecasts for 2025 and 2026 have been raised by 2% to 72.5 billion and 81.7 billion respectively, driven by the strong demand for flu products and the ongoing trend of original research products [1] - The company is expected to achieve a year-on-year revenue growth of approximately 25% in 2025, with strong quarterly performance observed in the first three quarters [2] - The non-IFRS net profit for 2025 and 2026 has been adjusted upwards by 4% and 1% to 6.5 billion and 6.4 billion respectively, with a new revenue forecast for 2027 set at 91.2 billion and non-IFRS net profit at 6.8 billion [1] Group 2 - The company has shown a steady improvement in non-IFRS net profit margins, with rates of 10.6%, 9.7%, and 11.1% in the first three quarters of 2025, attributed to increased marketing investments by pharmaceutical and health product companies [3] - Despite the potential fluctuations in interest income due to cash management strategies, the overall profit performance is expected to remain robust, reflecting the company's strong competitive position [3] - The company has signed strategic cooperation agreements with major pharmaceutical firms, enhancing its business model for new drug launches [2]

Group 1 - Morgan Stanley released a deep report on Ping An, highlighting its potential to seize key growth opportunities in wealth management, healthcare, and elderly care [3] - Ping An Good Doctor is identified as a crucial anchor in this "value reassessment," strategically positioned within Ping An's healthcare services and integrated financial business [3] - The report draws parallels with the HMO (Health Maintenance Organization) model validated by UnitedHealth Group over half a century, suggesting that Ping An Good Doctor is not merely replicating this model but is reconstructing it to fit the Chinese market [3] Group 2 - The core logic of both models revolves around "deep binding of payment and service," shifting from "post-service reimbursement" to "full-cycle health management" [3] - Ping An Good Doctor leverages Ping An Group's strategy of "integrated finance + healthcare and elderly care," creating a service network that addresses issues like uneven medical resource distribution and accelerated aging [3]

Core Viewpoint - China Ping An's stock price surged to a five-year high, positively impacting the Hong Kong market, particularly Ping An Good Doctor (1833.HK), which saw a significant increase of 9%, reaching its highest level since October 2025 [1] Group 1: Company Performance - Ping An Good Doctor is a key player in the "value re-evaluation" process, benefiting from its strategic position within the Ping An ecosystem, particularly in health and elderly care services [1] - The stock price increase of Ping An Good Doctor reflects a broader trend in the internet healthcare sector, indicating strong investor confidence [1] Group 2: Analyst Insights - Morgan Stanley's report from December 2025 highlighted Ping An's potential to capitalize on growth opportunities in personal finance, healthcare, and elderly care, raising its target price to 89 HKD [1] - Analysts suggest that Ping An Good Doctor is positioned to experience a "Davis Double Play" in terms of performance and valuation, particularly within the context of China's aging economy narrative [1]

Group 1 - Ping An Good Doctor (01833) saw a nearly 9% intraday increase, currently up 7.41% at HKD 15.66, with a trading volume of HKD 267 million [1] - Morgan Stanley's recent report on Ping An highlights the company's potential to capitalize on key growth opportunities in wealth management, healthcare, and elderly care [1] - Ping An Good Doctor is identified as a crucial anchor in this "value reassessment," leveraging its strategic position within Ping An's healthcare services to create a differentiated advantage [1] Group 2 - The report draws parallels with the HMO (Health Maintenance Organization) model validated by UnitedHealth Group over the past fifty years, suggesting that Ping An Good Doctor's adaptation is not a mere replication but a tailored version for the Chinese market [1] - The core logic of both models is similar, focusing on "deep integration of payment and services," shifting from "post-service reimbursement" to "full-cycle health management" [1] - Ping An Good Doctor's strategy, supported by Ping An Group's comprehensive financial and healthcare services, aims to address issues such as uneven medical resource distribution and accelerated aging through a "four-point service network" [1]